Last reviewed · How we verify

Antiandrogen Therapy — Competitive Intelligence Brief

Antiandrogen Therapy (Antiandrogen Therapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen receptor antagonist / Hormonal therapy. Area: Oncology.

phase 3 Androgen receptor antagonist / Hormonal therapy Androgen receptor (AR) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Antiandrogen Therapy (Antiandrogen Therapy) — M.D. Anderson Cancer Center. Antiandrogen therapy blocks the effects of androgens (male hormones) by inhibiting androgen receptor signaling, thereby slowing or stopping the growth of androgen-dependent cancer cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Antiandrogen Therapy TARGET Antiandrogen Therapy M.D. Anderson Cancer Center phase 3 Androgen receptor antagonist / Hormonal therapy Androgen receptor (AR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen receptor antagonist / Hormonal therapy class)

  1. M.D. Anderson Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Antiandrogen Therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/antiandrogen-therapy. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: